Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Right Drug Dose Now Act This bill sets out requirements and activities to address adverse drug events, including using pharmacogenomic testing to prevent them. (Pharmacogenomic testing uses a patient's genetic information to help determine the safety, efficacy, and dosage of medications for treatments.) Specifically, the Department of Health and Human Services (HHS) must report to Congress about the implementation of a national plan to prevent adverse drug events. Additionally, HHS must coordinate with relevant federal agencies on the report and convene a steering committee to update the plan. HHS must also (1) require, as a condition of certification, that health information technologies automatically indicate when pharmacogenomic testing is appropriate before a medication order is completed; and (2) assess electronic health records to identify improvements necessary for developing the capacity for collecting real-world evidence in pharmacogenomics. Furthermore, HHS must consult with the Food and Drug Administration (FDA) to carry out a program to improve reporting of adverse drug events and their association with a patient's genetic status. In addition, the FDA must issue regulations and make other administrative changes to update adverse drug event reporting processes, including to facilitate the acceptance of information directly from electronic health records. The bill also requires the National Human Genomics Research Institute, which is part of the National Institutes of Health, to (1) carry out a public awareness campaign on adverse drug events, and (2) establish a program to educate health care providers and related professionals about pharmacogenomic testing and associated issues.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (6)
2022 · second_quarter · Health Issues
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
H.R. 6000 Cures 2.0 Act H.R.6875 - Right Drug Dose Now Act S.3799 - PREVENT Pandemics Act Cancer Moonshot
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
2022 · fourth_quarter · Health Issues
Congressional Personalized Medicine Caucus H.R. 5989 Precision Medicine Answers for Kids Today Act H.R. 6000 Cures 2.0 H.R. 6875 Right Drug Dose Now Act H.R. 4128/S.2209 The VALID Act of 2021 H.R. 2144/S. 1450 Access to Genetic Counselors Services Act H.R. 5376 Inflation Reduction Act of 2022 Food and Drug Omnibus Reform Act of 2022 Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $38,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R.3: Reconciliation Build Back Better Act Co-Pay Accumulators H.R.7213, Equitable Community Access to Pharmacist Services Act H.R.6875, Right Drug Dose Now Act H.R. 1946/S. 1873, Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R. 6000 Cures 2.0 Act H.R.6875 - Right Drug Dose Now Act Diversity in clinical trials Health equity
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
2022 · third_quarter · Health Issues
Congressional Personalized Medicine Caucus H.R. 5989 Precision Medicine Answers for Kids Today Act H.R. 6000 Cures 2.0 H.R. 6875 Right Drug Dose Now Act H.R. 4128/S.2209 The VALID Act of 2021 and S.4348 FDASLA Act of 2022 H.R. 5376 Inflation Reduction Act of 2022 Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community CMS Medicare Advantage Request for Information CMS Calendar Year 2023 Physician Fee Schedule Proposed Rule CMS/CMMI Enhancing Oncology Model
Client expense: $39,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
H.R.3: Reconciliation Build Back Better Act Co-Pay Accumulators H.R.7213, Equitable Community Access to Pharmacist Services Act H.R.6875, Right Drug Dose Now Act H.R. 1946/S. 1873, Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021
Client expense: $170,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
H.R. 6000 Cures 2.0 Act H.R.6875 - Right Drug Dose Now Act Cancer Moonshot
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · second_quarter · Health Issues
H.R.3: Reconciliation Build Back Better Act Co-Pay Accumulators H.R.7213, Equitable Community Access to Pharmacist Services Act H.R.6875, Right Drug Dose Now Act
Client expense: $170,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Health Issues
Congressional Personalized Medicine Caucus H.R. 5989 Precision Medicine Answers for Kids Today Act H.R. 6000 Cures 2.0 H.R. 6875 Right Drug Dose Now Act H.R. 4128/S.2209 The VALID Act of 2021 Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community CMS Transitional Coverage of Emerging Technology (TCET) CMS Transmittal 10832 Removal of ICD-10 Not Otherwise Specified (NOS) Codes Under National Coverage Determination (NCD) 90.2 Reimbursement for Chimeric antigen receptor T cell therapy in FY 2023 IPPS Proposed Rule
Client expense: $48,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Health Issues
H.R. 6000 Cures 2.0 Act H.R.6875 - Right Drug Dose Now Act S.3799 - PREVENT Pandemics Act Cancer Moonshot
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
2022 · second_quarter · Health Issues
H.R. 6000 Cures 2.0 Act H.R.6875 - Right Drug Dose Now Act S.3799 - PREVENT Pandemics Act Cancer Moonshot
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
2022 · second_quarter · Health Issues
Specific Issue Descriptions: Healthcare issues related to clinical laboratories; H.R. 8188/S. 4449, the Saving Access to Laboratory Services Act (SALSA), provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, included as Subtitle C of Title VIII of S. 4348, the FDA Safety and Landmark Advancements Act (FDASLA), provisions relating to FDA oversight of laboratory-developed tests; H.R. 6202, the Telehealth Extension Act, and H.R. 7573/S. 3593, the Telehealth Extension and Evaluation Act, provisions relating to extension of Medicare coverage of telehealth services and limitations on payment for certain laboratory tests; H.R. 8152, the American Data Privacy and Protection Act (ADPPA), provisions relating to data privacy; S. 3799, the PREVENT Pandemics Act, and a draft of the Improving DATA in Public Health Act, provisions relating to demographic data reporting obligations for laboratories; H.R. 2144, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5030/S. 2706, the DIVERSE Trials Act, provisions relating to enhancing diversity in clinical trials and data collection and reporting by clinical laboratories; H.R. 6000, the Cures 2.0 Act, provisions relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing; H.R. 6875, the Right Drug Dose Now Act, provisions relating to use of pharmacogenetic information; H.R. 2565/S. 2952, the FDA Modernization Act, provisions relating to biomedical research; Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests; Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests; Federal policy relating to the National Correct Coding Initiative and manual instructions inconsistent with American Medical Association guidelines for Current Procedural Terminology (CPT) coding; and Federal policy relating to availability of Current Procedural Terminology (CPT) codes.
2022 · first_quarter · Health Issues
H.R.3: Reconciliation Build Back Better Act Co-Pay Accumulators H.R.7213, Equitable Community Access to Pharmacist Services Act H.R.6875, Right Drug Dose Now Act
Client expense: $20,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
H.R.4943, Childrens Mental Health Infrastructure Act of 2021 H.R.4944, Helping Kids Cope Act of 2021 S. 346 and H.R. 959, Black Maternal Health Momnibus Act of 2021 S. 2741 and H.R. 5247, The Reducing Obesity in Youth Act (ROYA) of 2021 S. 1357 and H.R. 3773, The Pediatricians Accelerate Childhood Therapies (PACT) Act of 2021 S. 509, LINC To Address Social Needs Act S.168 and H.R.708, Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act H.R.3549, Comprehensive Mental Health in Schools Pilot Program Act of 2021 S.1841 and H.R.721, Mental Health Services for Students Act S.3799 - PREVENT Pandemics Act H.R.6875 - Right Drug Dose Now Act Give Kids a Chance Act (Draft Senate version, no bill # yet) NIH IMPROVE ACT (no bill #) S.3628 - Youth Mental Health and Suicide Prevention Act Integrated behavioral health care act (Draft bill) (Senate bill)
Client expense: $186,520 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
Congressional Personalized Medicine Caucus H.R. 5989 Precision Medicine Answers for Kids Today Act S. 2022 Ending the Diagnostic Odyssey Act H.R. 6000 Cures 2.0 H.R. 6875 Right Drug Dose Now Act H.R. 4128/S.2209 The VALID Act of 2021 H.R. 6202 the Telehealth Extension Act S. 3593 the Telehealth Extension and Evaluation Act Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community CMS Transitional Coverage of Emerging Technology (TCET) CMS Transmittal 10832 Removal of ICD-10 Not Otherwise Specified (NOS) Codes Under National Coverage Determination (NCD) 90.2 CMMI Oncology Care Model/Oncology Care First
Client expense: $42,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
H.R. 6000 Cures 2.0 Act H.R.6875 - Right Drug Dose Now Act S.3799 - PREVENT Pandemics Act Cancer Moonshot
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
2022 · first_quarter · Health Issues
Increasing access to mental health and substance use treatment; H.R. 1364 - Parity Enforcement Act; H.R. 7116 - 9-8-8 Implementation Act; S. 4003 - Law Enforcement De-escalation Act; H.R. 6875 - Right Drug Dose Now Act; H.R. 1384/S. 445 - Mainstreaming Addiction and Treatment Act.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · first_quarter · Health Issues
Healthcare issues related to clinical laboratories; H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests; Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests; H.R. 6202, the Telehealth Extension Act, and S. 3593, the Telehealth Extension and Evaluation Act, provisions relating to extension of Medicare coverage of telehealth services and limitations on payment for certain laboratory tests; S. 3534, the Tracking Pathogens Act, provisions relating to genomic sequencing of variants of the SARS-CoV-2 virus; S. 3799, the PREVENT Pandemics Act, and a draft of the Improving DATA in Public Health Act, provisions relating to demographic data reporting obligations for laboratories; Federal policy related to the National Correct Coding Initiative and manual instructions inconsistent with American Medical Association guidelines for Current Procedural Terminology (CPT) coding; H.R. 2144, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 4144/S. 2022, the Ending the Diagnostic Odyssey Act, provisions relating to coverage of whole genome sequencing services for certain individuals; H.R. 5030/S. 2706, the DIVERSE Trials Act, provisions relating to enhancing diversity in clinical trials and data collection and reporting by clinical laboratories; Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 6000, the Cures 2.0 Act, provisions relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing; H.R. 4144/S. 2022, the Ending the Diagnostic Odyssey Act, provisions relating to coverage of whole genome sequencing services for certain individuals; and H.R. 6875, the Right Drug Dose Now Act, provisions relating to use of pharmacogenetic information; H.R. 2565/S. 2952, the FDA Modernization Act, provisions relating to biomedical research; and Federal policy relating to CDC funding for standardization of pediatric reference range intervals and laboratory result harmonization.
Client expense: $250,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $280,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE